Oligonucleotide therapeutics and diagnostics have moved from the periphery of drug development to its center. With that shift comes a higher analytical bar: a sequence that looks right is not the same as a product that is proven right. Confidence comes from characterization — rigorous, orthogonal, and documented.
The characterization challenge
Oligonucleotides are long, highly modified, and chemically similar to many of their own impurities. Failed couplings, depurination, and process-related variants can all produce species that differ from the target by a single unit. Distinguishing the product from its near-neighbors is where careful analytics earn their place.
Why orthogonal methods matter
No single technique tells the whole story. We pair complementary methods so that the strengths of one cover the blind spots of another:
- Liquid chromatography–mass spectrometry for identity and accurate mass confirmation.
- Ion-exchange and reversed-phase HPLC for purity and resolution of closely related species.
- Orthogonal assays for content, counter-ion, and water, so that the certificate reflects the full picture.
Identity is necessary but not sufficient. Confidence comes from agreement across independent methods.
Controlling impurities
The aim is not only to detect impurities but to understand and control them. By characterizing process-related species during development, we can set meaningful specifications and design the process to stay comfortably within them — rather than discovering surprises at release.
From sequence to release
A release-ready oligonucleotide is one whose identity, purity, and impurity profile are all demonstrated and documented to a standard a regulator would accept. That is the difference between a sequence that works in principle and a product a partner can build a program on.
Published by Global Biotech Laboratories. The information above is provided for general information and does not constitute regulatory, medical, or legal advice.